Ratings by Rothschild Redburn (Jamie Clark)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/17/2026 | ICON plc | ICLR | Downgrade | Neutral (Buy) |
80.08 (164.85) |
105.86% | Details | |
| 11/21/2025 | Certara Inc. | CERT | New Coverage | Buy (N/A) |
8.29 (7.94) |
-4.22% | Details | |
| 9/15/2025 | West Pharmaceutical | WST | New Coverage | Buy (N/A) |
263.74 (339.97) |
28.9% | Details | |
| 9/3/2025 | Iconix Brand | ICON | Upgrade | Buy (Neutral) |
1.92 (0.91) |
-52.6% | Details | |
| 9/3/2025 | Medpace | MEDP | Downgrade | Neutral (Buy) |
475.51 (591.29) |
24.35% | Details | |
| 9/3/2025 | ICON plc | ICLR | Upgrade | Buy (Neutral) |
177.94 (80.08) |
-55% | Details | |
| 5/23/2025 | Charles River Labs | CRL | Upgrade | Buy (Neutral) |
134.98 (288.50) |
113.74% | Details | |
| 4/2/2025 | Quest Diagnostics | DGX | New Coverage | Buy (N/A) |
169.20 (237.14) |
40.15% | Details | |
| 4/2/2025 | Laboratory Corporation of America | LH | New Coverage | Buy (N/A) |
232.74 (326.89) |
40.45% | Details | |
| 3/3/2025 | Charles River Labs | CRL | Upgrade | Neutral (Sell) |
164.88 (134.98) |
-18.13% | Details |
